Table of contents
- Clinical trials overview
- Rheumatoid arthritis studies
- Studies in other conditions
- Who can join these trials
- What the trials measure
- Trial phases and study designs
- Key points for patients
Clinical trials overview
The trial data show that Abatacept is being studied in several interventional trials, mostly in rheumatoid arthritis, but also in IgG4-related disease, giant cell arteritis, COVID-19, and juvenile idiopathic arthritis.[1][2][3][4][5][6][7][8][9][10][11][12][13]
Most of these studies are in Phase 3, which means they are larger trials that compare treatments and measure how well they work in real patient groups.[3][4][5][6][7][8][9][10][11][12][13][2]
The studies are designed to test safety, efficacy (how well a treatment works), remission, relapse prevention, and whether certain markers can help predict who will respond best.[1][2][3][4][5][6][7][8][9][10][11][12][13]
Rheumatoid arthritis studies
Rheumatoid arthritis is the main condition studied in the trial set, with multiple trials in early disease, moderate to severe disease, and treatment-resistant disease.[1][3][6][7][8][9][10][13]
One Phase 1 study is looking at a combination approach in ACPA-positive rheumatoid arthritis, meaning patients have a specific antibody linked to the disease, and it measures safety events such as injection-related reactions and changes in ACPA status over 12 weeks.[1]
Several Phase 3 trials focus on whether Abatacept can improve disease control in people with early rheumatoid arthritis, including patients who are seropositive (RF+ and ACPA+) and those with specific genetic risk markers.[6][3]
These trials measure outcomes such as remission, ACR50 response (a 50% improvement score used in arthritis research), CDAI (a clinical disease activity score), DAS28-CRP (a disease activity score using joint counts and a blood marker), and radiographic progression, which means joint damage seen on imaging over time.[3][6][7][8][9]
Some studies compare Abatacept with other active treatments, such as adalimumab or tocilizumab, while others compare treatment strategies, such as using Abatacept after a first TNF inhibitor or testing whether certain tissue biomarkers can predict response.[6][7][8][9]
One trial also studies a proposed Abatacept biosimilar, meaning a medicine designed to be highly similar to the original product, and compares efficacy, safety, and immunogenicity, which is the body’s immune response to the treatment.[8]
Studies in other conditions
In IgG4-related disease, a Phase 2 trial is testing whether Abatacept can reduce disease recurrence over 48 weeks compared with placebo, which is an inactive treatment used as a comparison.[2]
In giant cell arteritis, a randomized, double-blind, placebo-controlled Phase 3 study is measuring the proportion of patients in remission at Month 12.[4]
In hospitalized adults with COVID-19, Abatacept was studied in a large Phase 3 platform trial called STRIVE, where the main outcome was the Days to Recovery Scale over 60 days, a recovery measure that also includes not-recovered status and death.[5]
In children and adolescents with juvenile idiopathic arthritis, Abatacept appears in trials that study drug withdrawal strategies after remission and compare treatment options after TNF inhibitor failure.[10][11]
These pediatric studies focus on whether treatment can be safely tapered or changed while keeping disease under control, using outcomes such as flare rates and minimal disease activity.[10][11]
Who can join these trials
Eligibility is different for each study, but the trial data show several main patient groups.[1][2][3][4][5][6][7][8][9][10][11][13]
Adults with rheumatoid arthritis, including early disease, moderate to severe disease, or disease that has not responded well to previous therapy.[3][6][7][8][9][13]
Patients with specific immune markers, such as ACPA-positive or seropositive rheumatoid arthritis, where the studies try to see if these markers predict response.[1][6][7]
Hospitalized adults with COVID-19, in a study of recovery after respiratory infection.[5]
Adults with IgG4-related disease or giant cell arteritis, where the goal is to lower recurrence or increase remission.[2][4]
Children with juvenile idiopathic arthritis, especially those in remission or those who have failed TNF inhibitor treatment.[10][11]
What the trials measure
The main outcomes are chosen to show whether the disease is better controlled and whether the treatment is safe.[1][2][3][4][5][6][7][8][9][10][11][13]
Remission, meaning the disease is very quiet or inactive.[2][4][6][9]
Low disease activity, meaning symptoms and signs are present but not severe.[13]
Clinical response scores such as ACR50, CDAI, and DAS28-CRP, which are common ways to measure arthritis improvement.[3][6][7][8][9][13]
Radiographic progression, which means joint damage seen on X-ray or similar imaging over time.[7]
Safety events, including injection-related reactions, adverse events, and serious adverse events.[1][8]
Flare rates and drug withdrawal outcomes, especially in juvenile idiopathic arthritis studies that test whether treatment can be reduced safely.[10][11]
Trial phases and study designs
The trial set includes a mix of study designs, but most are interventional, meaning researchers assign the treatment being studied.[1][2][3][4][5][6][7][8][9][10][11][13]
There is one Phase 1 trial in rheumatoid arthritis, which is centered on safety and early signals of response.[1]
There is one Phase 2 trial in IgG4-related disease, which focuses on recurrence prevention over 48 weeks.[2]
The rest of the listed studies are mainly Phase 3 trials, which compare Abatacept with placebo or other active treatments, or compare treatment strategies in larger patient groups.[3][4][5][6][7][8][9][10][11][13]
One rheumatoid arthritis study is listed as Low Intervention, meaning the trial compares treatment strategies with limited extra intervention from the study itself.[13]
Key points for patients
These trials show that Abatacept is being studied across different stages of disease and different age groups, from children to adults.[1][2][3][4][5][6][7][8][9][10][11][13]
Some studies are trying to find the best time to start, switch, taper, or stop treatment, while others compare Abatacept with placebo or with other medicines.[2][4][5][6][7][9][10][11][13]
Overall, the research is focused on finding better ways to control immune-related disease and to identify which patients are most likely to benefit from treatment.[1][2][3][4][5][6][7][8][9][10][11][13]
